Receive a complete Daily History of this Stock You can receive a complete daily file of this issue since 1970 or stock inception. We will email you the file in ASCII format within a few hours or ordering. Product Details | Order

Business Description
Eli Lilly and Company discovers, develops, manufactures and sells pharmaceutical products. The Company's largest category of products is the neurosciences group, which includes Zyprexa, Prozac, Strattera and Permax. Endocrinology products consist primarily of Humulin, Humalog, Actos, Evista, Forteo and Humatrope. Oncology products consist primarily of Gemzar. Animal health products include Tylan, Rumensin, Coban and other products for livestock and poultry. Cardiovascular products consist primarily of ReoPro and Xigris. Anti-infectives include primarily Ceclor and Vancocin. The other pharmaceutical product group includes Cialis, Axid and other miscellaneous pharmaceutical products and services. Most of the Company's pharmaceutical products are distributed through wholesalers that serve pharmacies, physicians and other healthcare professionals, and hospitals. Eli Lilly's products are sold in approximately 140 countries.

Financial Information
For the nine months ended 9/30/04, net sales rose 12% to $10.21 billion. Net income fell less than 1% to $1.81 billion. Revenues reflect the strong performances of Zyprexa, Humalog, Gemzar and Evista and the recent launches of Strattera, Cialis and Forteo. Earnings were offset by lower gross margins and a higher effective tax rate.